BE2015C078I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C078I2
BE2015C078I2 BE2015C078C BE2015C078C BE2015C078I2 BE 2015C078 I2 BE2015C078 I2 BE 2015C078I2 BE 2015C078 C BE2015C078 C BE 2015C078C BE 2015C078 C BE2015C078 C BE 2015C078C BE 2015C078 I2 BE2015C078 I2 BE 2015C078I2
Authority
BE
Belgium
Application number
BE2015C078C
Other languages
Dutch (nl)
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2015C078(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of BE2015C078I2 publication Critical patent/BE2015C078I2/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/08Mydriatics or cycloplegics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BE2015C078C 2002-07-30 2015-12-18 BE2015C078I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39989902P 2002-07-30 2002-07-30
PCT/US2003/023871 WO2004010894A2 (en) 2002-07-30 2003-07-30 Ophthalmologic irrigation solutions and method

Publications (1)

Publication Number Publication Date
BE2015C078I2 true BE2015C078I2 (de) 2022-08-09

Family

ID=31188639

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C078C BE2015C078I2 (de) 2002-07-30 2015-12-18

Country Status (18)

Country Link
US (10) US20040072809A1 (de)
EP (1) EP1534313B1 (de)
JP (11) JP2006504661A (de)
CN (3) CN1684701B (de)
AU (2) AU2003261304A1 (de)
BE (1) BE2015C078I2 (de)
CA (2) CA2866848C (de)
CY (1) CY2015055I1 (de)
DK (1) DK1534313T3 (de)
ES (1) ES2397574T3 (de)
FR (1) FR15C0090I2 (de)
HK (1) HK1081455A1 (de)
HU (1) HUS1500069I1 (de)
LU (1) LU92923I2 (de)
NL (1) NL300784I2 (de)
PT (1) PT1534313E (de)
SI (1) SI1534313T1 (de)
WO (1) WO2004010894A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684701B (zh) 2002-07-30 2012-10-17 奥默罗斯公司 眼科冲洗液及方法
US8748402B2 (en) 2004-06-07 2014-06-10 Bausch & Lomb Pharma Holdings Corp. Ophthalmic formulations and uses thereof
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PL2465534T3 (pl) 2004-06-10 2017-08-31 Omeros Corporation Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
US7592371B2 (en) * 2004-08-18 2009-09-22 Medrx Co., Ltd. External preparation
FR2882930B1 (fr) * 2005-03-09 2009-03-27 Walid Katib Nouvelles compositions ophtalmologiques et leur mode d'utilisation
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery
MX2009005644A (es) * 2006-12-22 2009-06-08 Sigma Tau Ind Farmaceuti Gel util para el suministro de farmacos oftalmicos.
US20100240713A1 (en) * 2007-06-05 2010-09-23 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
CN101347620B (zh) * 2007-07-20 2012-04-25 天津药业研究院有限公司 一种药物组合物及其在制备治疗青光眼的药物中的应用
WO2010050211A1 (ja) 2008-10-30 2010-05-06 国立大学法人 岡山大学 局所麻酔用組成物
WO2010053487A1 (en) * 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010107525A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
GB0915319D0 (en) * 2009-09-03 2009-10-07 Sharma Anant Combination medicament
KR101788040B1 (ko) 2009-10-16 2017-10-19 오메로스 코포레이션 Masp-2 의존성 보체 활성화의 억제에 의한 파종성 혈관내 응고의 치료 방법
BR112013021048A2 (pt) * 2011-02-18 2016-10-18 M S Appasmy Associates composição oftálmica para permitir dilatação de pupilas
ITPA20110004A1 (it) * 2011-02-23 2012-08-24 Francesco Paolo Montalto Iniezione intracamerulare per anestesia e dilatazione pupillare (midriasi).
KR20210021101A (ko) 2011-04-08 2021-02-24 유니버시티 오브 레스터 Masp-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2013201465B2 (en) * 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
RU2525512C1 (ru) * 2013-03-28 2014-08-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ медикаментозного расширения ригидного зрачка перед проведением факоэмульсификации
CA3050457C (en) * 2013-05-06 2021-05-25 Kaohsiung Chang Gung Memorial Hospital A pharmaceutical composition comprising atropine and nsaid for treating myopia
RU2529787C1 (ru) * 2013-06-03 2014-09-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Офтальмологический ирригационный раствор
WO2015026423A1 (en) 2013-08-20 2015-02-26 Infusion Medical, Inc. Syringe fill system and method
MX2016004257A (es) 2013-10-03 2016-08-17 Imprimis Pharmaceuticals Inc Composiciones oftalmicas basadas en epinefrina para la administracion intraocular y metodos para su frabricacion.
US10981951B2 (en) 2014-01-31 2021-04-20 Mayo Foundation For Medical Education And Research Therapeutics for the treatment of glaucoma
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
CN104324049A (zh) * 2014-09-26 2015-02-04 浙江天瑞药业有限公司 一种制备关节手术用平衡盐冲洗液的方法
TWI705812B (zh) * 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CN104856990A (zh) * 2015-05-07 2015-08-26 武汉武药科技有限公司 去氧肾上腺素酮咯酸溶液及制备方法
CN105213418B (zh) * 2015-11-11 2019-01-22 中国人民解放军第四军医大学 一种眼科术前用复方滴眼液及其制备方法
US10220012B2 (en) * 2016-06-03 2019-03-05 Joerg H. KRUMEICH Solution for ophthalmology
US10231968B2 (en) 2016-08-01 2019-03-19 David R. Hardten Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies
CA3034640A1 (en) 2016-08-25 2018-03-01 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
CA3035561A1 (en) * 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
CN107137713A (zh) * 2017-05-12 2017-09-08 浙江工贸职业技术学院 一种眼科手术后用冲洗液及其制备方法
JP2020523312A (ja) * 2017-06-08 2020-08-06 アイ・セラピーズ・エル・エル・シー 低用量ブリモニジンの組み合わせおよびその使用
WO2019094390A1 (en) * 2017-11-10 2019-05-16 The Regents Of The University Of Colorado, A Body Corporate Methods for inducing pupil dilation
EP3681500B1 (de) 2018-04-24 2022-03-23 Allergan, Inc. Verwendung von pilocarpinhydrochlorid zur behandlung von presbyopie
KR20240027865A (ko) 2019-03-11 2024-03-04 닛폰 호소 교카이 화상 부호화 장치, 화상 복호 장치 및 프로그램
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
WO2021158992A1 (en) * 2020-02-07 2021-08-12 Qlaris Bio, Inc. Improved methods and compositions for cromakalim prodrug therapy
US11883382B2 (en) 2021-07-23 2024-01-30 Somerset Therapeutics, Llc Buffer-free ophthalmological compositions of ketorolac and phenylephrine and applications thereof
US12029729B2 (en) 2021-07-23 2024-07-09 Somerset Therapeutics, Llc Chelated, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof
JPWO2023048174A1 (de) * 2021-09-22 2023-03-30

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
WO1987007141A1 (en) 1986-05-23 1987-12-03 New England Medical Center Hospitals, Inc. Method for treating glaucoma
US5212196A (en) * 1986-10-21 1993-05-18 Alcon Laboratories, Inc. Control of post-surgical intraocular pressure using clonidine derivatives
US4938970A (en) * 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5036046A (en) 1988-10-12 1991-07-30 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5051443A (en) 1988-10-12 1991-09-24 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5116868A (en) * 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
ATE135216T1 (de) 1989-08-21 1996-03-15 Beth Israel Hospital Verwendung von spiperone-derivate zur immunosuppression
CA2073003A1 (en) 1990-09-07 1992-03-08 Universidad De Alicante Composition for treating ocular pain
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
JPH07502544A (ja) * 1992-10-21 1995-03-16 アルコン ラボラトリーズ,インコーポレイテッド 眼内組織潅注用および眼内外科処置中の瞳孔散大維持用組成物
US6117907A (en) * 1993-04-14 2000-09-12 Sher; Neal A. Topical treatment of ocular pain after corneal surgery
WO1995009004A1 (en) * 1993-09-29 1995-04-06 Alcon Laboratories, Inc. Compositions containing growth factors and antiplastic agents
AU7846794A (en) 1993-09-29 1995-04-18 Alcon Laboratories, Inc. Compositions containing growth factors and antimetabolites
US5624893A (en) * 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
EP0734248A1 (de) * 1993-12-17 1996-10-02 Alcon Laboratories, Inc. Nicht-steroidale antiinflammatorische wirkstoffe enthaltende verbesserte intrakokulare irrigationslösung
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
WO1995034298A1 (en) 1994-06-10 1995-12-21 Telor Ophthalmic Pharmaceuticals, Inc. Inhibition of intraoperative miosis/production of mydriasis by local anesthetics
US5523316A (en) * 1994-06-23 1996-06-04 Alcon Laboratories, Inc. Intraocular irrigating solution containing agent for controlling IOP
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
RU2180852C2 (ru) 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ,インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
WO2000023062A2 (en) 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
KR100517210B1 (ko) 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
US7091181B2 (en) * 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
WO2000023061A2 (en) 1998-10-21 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
WO2000023066A2 (en) 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5767105A (en) * 1995-05-03 1998-06-16 Peyman; Gholam A. Ocular solution
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6413961B1 (en) * 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6280745B1 (en) * 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
EP1039818A4 (de) 1996-07-26 2001-11-07 Schein Dental Equipment Co Armlehnemechanismus für einen zahnärtzlichen patientenstuhl
GB9704352D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6495598B1 (en) * 1997-04-22 2002-12-17 Ophtecs Corporation Perfusate preparation for ophthalmic operation
EP0903151A1 (de) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Verwendung von Kombinationen enthaltend nichtsedierende Antihistaminika und Alfa-Adrenergische Agonisten für die topische Behandlung von Rhinitis/Konjunktivitis sowie Erkältungs- und Grippe-Symptomen
US6495529B1 (en) * 1998-07-01 2002-12-17 Warner-Lambert Company (−)-Pseudoephedrine as a sympathomimetic drug
EP1037627B1 (de) * 1998-07-14 2001-08-01 Alcon Laboratories, Inc. Verwendung von 11-(3-dimethylaminopropyliden)-6,11-dihydrodibenz[b,e]oxepin-2-essigsäure und deren pharmazeutisch annehmbaren salzen zur herstellung eines medikaments zur behandlung nicht-allergisch-bedingten augenentzündungen und zur prevention der okularen neovaskularisation
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AU1127700A (en) 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
AU1345000A (en) 1998-11-05 2000-05-22 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6433007B1 (en) 1998-12-17 2002-08-13 Alcon Manufacturing, Ltd. Methods for the prevention and treatment of post-surgical complications
PL351710A1 (en) * 1999-05-14 2003-06-02 Univ California Anti−inflammatory therapy for inflammatory mediated infection
US7273887B1 (en) * 1999-10-22 2007-09-25 Transdermatech, Inc. Topical anesthetic formulation
CA2407683C (en) 2000-04-28 2010-04-13 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
CA2414674A1 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
ES2392636T3 (es) * 2000-07-14 2012-12-12 Allergan, Inc. Composiciones que contienen componentes terapéuticamente activos que tienen solubilidad mejorada
CN1450896A (zh) * 2000-07-28 2003-10-22 印斯拜尔药品股份有限公司 用吲哚衍生物降低眼内压的方法
JP2002161032A (ja) * 2000-09-14 2002-06-04 Taisho Pharmaceut Co Ltd 粘膜適用組成物
CN1390124A (zh) * 2000-09-20 2003-01-08 永光制药有限公司 近视眼的预防、治疗药
US20020183279A1 (en) * 2001-04-18 2002-12-05 Koichiro Tanaka Pharmaceutical composition containing viscoelastic substance and medication
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
CN1684701B (zh) 2002-07-30 2012-10-17 奥默罗斯公司 眼科冲洗液及方法
JP4950063B2 (ja) 2004-12-22 2012-06-13 シェーリング コーポレイション 薬学的製剤
US8303691B2 (en) 2008-04-08 2012-11-06 Fujifilm Manufacturing Europe B.V. Composite membranes
US20100311688A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
EP2437743A4 (de) 2009-06-05 2012-11-28 Aciex Therapeutics Inc Ophthalmische formulierungen aus fluticason und verfahren zu ihrer verwendung
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection

Also Published As

Publication number Publication date
JP2010132696A (ja) 2010-06-17
US20130065869A1 (en) 2013-03-14
SI1534313T1 (sl) 2013-03-29
JP2022132495A (ja) 2022-09-08
CY2015055I2 (el) 2016-06-22
US20140235597A1 (en) 2014-08-21
JP2016014056A (ja) 2016-01-28
JP2020169205A (ja) 2020-10-15
US20040072809A1 (en) 2004-04-15
HUS1500069I1 (hu) 2016-02-29
CY2015055I1 (el) 2016-06-22
CA2493581A1 (en) 2004-02-05
US20130079344A1 (en) 2013-03-28
ES2397574T3 (es) 2013-03-08
LU92923I2 (fr) 2016-02-23
NL300784I2 (nl) 2022-05-16
EP1534313B1 (de) 2012-10-17
CA2866848C (en) 2017-01-03
JP2019043965A (ja) 2019-03-22
PT1534313E (pt) 2013-01-25
US20160106761A1 (en) 2016-04-21
JP2018009033A (ja) 2018-01-18
CA2866848A1 (en) 2004-02-05
CN1684701B (zh) 2012-10-17
JP2016014055A (ja) 2016-01-28
US8173707B2 (en) 2012-05-08
HK1081455A1 (en) 2006-05-19
JP2006504661A (ja) 2006-02-09
EP1534313A2 (de) 2005-06-01
US20170100412A1 (en) 2017-04-13
WO2004010894A2 (en) 2004-02-05
JP2022132496A (ja) 2022-09-08
WO2004010894A3 (en) 2004-07-01
AU2009248461A1 (en) 2010-01-07
US9399040B2 (en) 2016-07-26
US20100311705A1 (en) 2010-12-09
DK1534313T3 (da) 2013-02-04
AU2009248461B2 (en) 2013-07-18
US20170312295A1 (en) 2017-11-02
US9278101B2 (en) 2016-03-08
NL300784I1 (de) 2015-12-30
CA2493581C (en) 2014-12-23
EP1534313A4 (de) 2008-06-25
FR15C0090I1 (de) 2016-01-22
JP2011006475A (ja) 2011-01-13
US9585895B2 (en) 2017-03-07
JP2013216705A (ja) 2013-10-24
AU2003261304A1 (en) 2004-02-16
FR15C0090I2 (fr) 2016-04-22
CN1684701A (zh) 2005-10-19
US20140221326A1 (en) 2014-08-07
US20220175797A1 (en) 2022-06-09
US8586633B2 (en) 2013-11-19
CN101327325A (zh) 2008-12-24
CN103143022A (zh) 2013-06-12

Similar Documents

Publication Publication Date Title
BE2019C547I2 (de)
BE2019C510I2 (de)
BE2018C021I2 (de)
BE2017C049I2 (de)
BE2017C005I2 (de)
BE2016C069I2 (de)
BE2016C040I2 (de)
BE2016C013I2 (de)
BE2018C018I2 (de)
BE2016C002I2 (de)
BE2015C078I2 (de)
BE2015C017I2 (de)
BE2014C053I2 (de)
BE2014C051I2 (de)
BE2014C041I2 (de)
BE2014C030I2 (de)
BE2014C016I2 (de)
BE2014C015I2 (de)
BE2013C063I2 (de)
BE2011C038I2 (de)
BRPI0302144A2 (de)
BRPI0215435A2 (de)
BE2013C046I2 (de)
JP2003247937A5 (de)
JP2003224516A5 (de)